Research programme: cancer therapeutics - Oxford BioMedica

Drug Profile

Research programme: cancer therapeutics - Oxford BioMedica

Alternative Names: Adoptive T-cell immunotherapies - Oxford BioMedica; CAR Immunotherapies - Oxford BioMedica; CART-5T4 programme - Oxford BioMedica; OXB-302

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Oxford BioMedica
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies
  • Mechanism of Action Immunostimulants; T-cell receptor gene modulators; T-lymphocyte differentiation antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Mar 2017 Research programme: cancer therapeutics - OXB 302 is available for licensing as of 16 Mar 2017. http://www.oxfordbiomedica.co.uk/pipeline/
  • 04 Nov 2014 Preclinical trials in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top